论文部分内容阅读
目的 评价重组人生长激素对肝炎后肝硬化患者低蛋白血症的影响。方法 治疗组31例肝硬化患者用重组人生长激素 (每日 0 2 5IU kg)、对照组 2 0例用人血白蛋白 (10g d)治疗 10d ,用放射免疫法测定治疗前、后 2 4h及治疗结束时的血清生长激素 (GH)、类胰岛素生长因子 (IGF) - 1、白蛋白 (ALB)水平 ,另以同样方法测定 10例健康人的GH、IGF - 1水平。结果 肝硬化患者治疗前的GH水平高于健康人 (4 96± 3 97,1 6 2± 2 2 6 ,P <0 .0 5 ) ,而IGF - 1水平明显低于健康人 (36 5 3±12 77,5 6 95± 10 46 ,P <0 .0 1)。经重组人生长激素治疗后 ,IGF - 1和ALB明显增高 ,与对照组比较差异有显著性 (P <0 .0 1)。结论 重组人生长激素可以克服肝硬化患者的生长激素抵抗现象 ;对其低蛋白血症的改善优于单纯人血白蛋白治疗
Objective To evaluate the effect of recombinant human growth hormone on hypoproteinemia in patients with posthepatitic cirrhosis. Methods Twenty-one patients with cirrhosis were treated with recombinant human growth hormone (021 IU kg daily), 20 patients in the control group were treated with 10 g of human serum albumin (10 g d) for 10 days, and the levels of IL- Serum GH, IGF - 1 and ALB levels were measured at the end of treatment. The GH and IGF - 1 levels were also measured in 10 healthy people by the same method. Results The levels of GH in patients with cirrhosis before treatment were significantly higher than those in healthy subjects (496 ± 3 97,1 62 ± 226, P <0.05), while the levels of IGF - 1 in patients with cirrhosis were significantly lower than those in healthy subjects ± 12 77,5 6 95 ± 10 46, P <0 01). IGF - 1 and ALB were significantly increased after recombinant human growth hormone treatment, which was significantly different from the control group (P <0.01). Conclusion Recombinant human growth hormone can overcome the growth hormone resistance in patients with cirrhosis; its hypoproteinemia is better than pure human serum albumin